NeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada

MT Newswires Live10-09

NeuroSense Therapeutics (NRSN) said Wednesday it will seek early approval from Canadian regulators to commercialize its prospective treatment for amyotrophic lateral sclerosis, or ALS.

The move is based on "promising" results from the phase 2b testing of the company's Prime C drug candidate in patients with ALS.

The company in July released additional results from the mid-stage study showing Prime C produced a 36% reduction in disease progression and a 43% improvement in survival rates compared with patients with ALS in the placebo group.

Health Canada allows drug makers to seek conditional marketing approval in Canada for their product candidates to treat serious, life-threatening or severely debilitating diseases with a promising clinical benefit, provided the company agrees to additional testing and the prospective treatment demonstrates an acceptable safety profile.

NeuroSense shares recently were 1.2% higher shortly after Wednesday's opening bell.

Price: 1.24, Change: +0.02, Percent Change: +1.23

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474222572?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-09 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474222572","market":"hk","top_or_hot":-1,"title":"NeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada","media":"MT Newswires Live","content":"<html><body><p> NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (NRSN) said Wednesday it will seek early approval from Canadian regulators to commercialize its prospective treatment for amyotrophic lateral sclerosis, or ALS.</p><p>The move is based on \"promising\" results from the phase 2b testing of the company's Prime C drug candidate in patients with ALS.</p><p>The company in July released additional results from the mid-stage study showing Prime C produced a 36% reduction in disease progression and a 43% improvement in survival rates compared with patients with ALS in the placebo group.</p><p>Health Canada allows drug makers to seek conditional marketing approval in Canada for their product candidates to treat serious, life-threatening or severely debilitating diseases with a promising clinical benefit, provided the company agrees to additional testing and the prospective treatment demonstrates an acceptable safety profile.</p><p>NeuroSense shares recently were 1.2% higher shortly after Wednesday's opening bell.</p><p>Price: 1.24, Change: +0.02, Percent Change: +1.23</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-09 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NeuroSense Therapeutics (NRSN) said Wednesday it will seek early approval from Canadian regulators to commercialize its prospective treatment for amyotrophic lateral sclerosis, or ALS.The move is ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2474222572","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474222572","pubTimestamp":1728481898,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"NeuroSense Therapeutics  said Wednesday it will seek early approval from Canadian regulators to commercialize its prospective treatment for amyotrophic lateral sclerosis, or ALS.The move is based on \"promising\" results from the phase 2b testing of the company's Prime C drug candidate in patients with ALS.The company in July released additional results from the mid-stage study showing Prime C produced a 36% reduction in disease progression and a 43% improvement in survival rates compared with patients with ALS in the placebo group.Health Canada allows drug makers to seek conditional marketing approval in Canada for their product candidates to treat serious, life-threatening or severely debilitating diseases with a promising clinical benefit, provided the company agrees to additional testing and the prospective treatment demonstrates an acceptable safety profile.NeuroSense shares recently were 1.2% higher shortly after Wednesday's opening bell.Price: 1.24, Change: +0.02, Percent Change: ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","NRSN":"Neurosense Therapeutics Ltd"},"translate_title":"NeuroSense Therapeutics寻求加拿大监管机构尽早批准前瞻性ALS治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"NRSN":0.9},"content_text":"NeuroSense Therapeutics (NRSN) said Wednesday it will seek early approval from Canadian regulators to commercialize its prospective treatment for amyotrophic lateral sclerosis, or ALS.The move is based on \"promising\" results from the phase 2b testing of the company's Prime C drug candidate in patients with ALS.The company in July released additional results from the mid-stage study showing Prime C produced a 36% reduction in disease progression and a 43% improvement in survival rates compared with patients with ALS in the placebo group.Health Canada allows drug makers to seek conditional marketing approval in Canada for their product candidates to treat serious, life-threatening or severely debilitating diseases with a promising clinical benefit, provided the company agrees to additional testing and the prospective treatment demonstrates an acceptable safety profile.NeuroSense shares recently were 1.2% higher shortly after Wednesday's opening bell.Price: 1.24, Change: +0.02, Percent Change: +1.23","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474222572"}